Amarin Corporation plc (AMRN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Amarin Corporation plc (AMRN) Healthcare & Pipeline Overview

Amarin Corporation plc is a biotechnology firm specializing in cardiovascular therapeutics, primarily commercializing VASCEPA, a prescription-only omega-3 fatty acid product. Headquartered in Dublin, Ireland, the company focuses on reducing triglyceride levels in adult patients with severe hypertriglyceridemia across markets including the U.S., Germany, and Canada, leveraging its core product and strategic collaborations.

What Is the Investment Thesis for AMRN?

Amarin Corporation plc presents an investment thesis centered on the established market presence of its lead product, VASCEPA, within the cardiovascular therapeutics segment. Despite a current negative profit margin of -15.6% and a market capitalization of $290M, the company's gross margin of 52.5% indicates strong product-level profitability. The value proposition is primarily driven by the ongoing commercialization and potential for increased market penetration of VASCEPA, a prescription-only omega-3 fatty acid product for severe hypertriglyceridemia. Growth catalysts include continued geographic expansion into markets like Germany, Canada, Lebanon, and the UAE, alongside potential new indications or product developments stemming from its collaboration with Mochida Pharmaceutical Co., Ltd. The company's focused approach on a critical cardiovascular risk factor, hypertriglyceridemia, addresses a significant patient population. Key risks involve the company's reliance on a single primary product, the highly competitive nature of the biotechnology and cardiovascular drug markets, and the need to achieve sustained profitability. The beta of 0.89 suggests relatively lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

AMRN Key Highlights

Market capitalization stands at $290M, reflecting its current valuation within the biotechnology sector.

• Reported a gross margin of 52.5%, indicating strong profitability at the product level for its lead therapeutic.
• Operates with a profit margin of -15.6%, highlighting current challenges in achieving overall profitability.
• Employs approximately 275 individuals, focusing on specialized pharmaceutical development and commercialization.
• Lead product, VASCEPA, is a prescription-only omega-3 fatty acid for severe hypertriglyceridemia, commercialized across multiple international markets.

Who Are AMRN's Competitors?

AMRN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AMRN's Key Strengths?

Lead product VASCEPA is a prescription-only omega-3 fatty acid with established efficacy for severe hypertriglyceridemia.

• Global commercialization footprint spanning the U.S., Germany, Canada, Lebanon, and UAE.
• Strategic collaboration with Mochida Pharmaceutical Co., Ltd. for potential new drug products and indications.
• Strong gross margin of 52.5% on its product sales.

What Are AMRN's Weaknesses?

Reliance on a single primary product, VASCEPA, for a significant portion of its revenue.

• Currently operating with a negative profit margin of -15.6%, indicating profitability challenges.
• Relatively small market capitalization of $290M compared to larger pharmaceutical competitors.
• Limited public information available regarding the specific track record of its CEO and detailed corporate history.

What Could Drive AMRN Stock Higher?

AMRN catalyst: Continued commercialization efforts for VASCEPA in existing and newly entered international markets, aiming to increase market penetration and sales volumes.

• Potential outcomes from the ongoing collaboration with Mochida Pharmaceutical Co., Ltd., which could lead to new drug products or expanded indications for eicosapentaenoic acid.
• Strategic initiatives to manage and strengthen VASCEPA's market position against competitive therapies in the cardiovascular disease segment.

What Are the Key Risks for AMRN?

Financial-distress signal — its Altman Z-Score of -1.88 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-7.3%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Intense competition within the cardiovascular therapeutics market, potentially impacting VASCEPA's market share and pricing power.
• Significant reliance on a single primary product, VASCEPA, for a substantial portion of the company's revenue, creating concentration risk.
• Regulatory changes or challenges in key operational geographies that could affect VASCEPA's market access, approval status, or pricing.
• Fluctuations in prescription volumes or market acceptance of VASCEPA, influenced by factors such as physician prescribing habits, patient adherence, and evolving treatment guidelines.

What Are the Growth Opportunities for AMRN?

• Geographic Expansion: Amarin is actively commercializing VASCEPA in several international markets beyond the U.S., including Germany, Canada, Lebanon, and the United Arab Emirates. This ongoing expansion represents a significant growth opportunity by tapping into new patient populations and healthcare systems. Each market presents unique regulatory, commercial, and competitive dynamics, but successful penetration can substantially increase VASCEPA's overall sales volume and market share. Leveraging its existing product's established efficacy and safety profile, Amarin can strategically allocate resources to maximize adoption in these regions, potentially driving revenue growth as market awareness and prescription rates increase over time.
• Enhanced Market Penetration for VASCEPA: Within its existing markets, particularly the United States, there remains significant potential for increased market penetration of VASCEPA among adult patients with severe hypertriglyceridemia. Despite its established presence, a substantial portion of the target patient population may still be undiagnosed or undertreated. Amarin can capitalize on this by intensifying educational initiatives for healthcare providers and patients, highlighting the clinical benefits of VASCEPA as an adjunct to diet. Expanding awareness of the link between elevated triglycerides and cardiovascular risk can drive greater diagnostic rates and subsequent prescription volumes, solidifying VASCEPA's position as a standard of care in this specific indication.
• Strategic Collaboration with Mochida Pharmaceutical: Amarin's collaboration with Mochida Pharmaceutical Co., Ltd. offers a distinct growth pathway by exploring new drug products and indications based on eicosapentaenoic acid, the active pharmaceutical ingredient in VASCEPA. This partnership could lead to the development of novel formulations or expanded therapeutic uses for the compound, potentially addressing broader cardiovascular conditions or different patient populations. Such developments could open up entirely new revenue streams and market segments, extending the lifecycle and value proposition of Amarin's core scientific expertise. The success of this collaboration hinges on ongoing research and development, with potential timelines for new product launches or expanded indications varying based on clinical trial outcomes and regulatory approvals.
• Addressing Unmet Needs in Cardiovascular Risk Management: The focus on severe hypertriglyceridemia positions Amarin to address a critical, often undertreated, component of cardiovascular risk. Despite advances in statin therapy, a significant residual risk remains for patients with elevated triglycerides. VASCEPA offers a targeted solution in this specific patient cohort. As understanding of lipid metabolism and cardiovascular disease evolves, and as healthcare systems increasingly prioritize preventative and risk-reduction strategies, Amarin's specialized product can gain further traction. This opportunity is driven by the persistent global burden of cardiovascular diseases and the ongoing need for comprehensive risk management strategies beyond traditional cholesterol lowering.
• Leveraging Specialized Distribution Channels: Amarin's strategy of selling products principally to wholesalers and specialty pharmacy providers represents a focused and efficient distribution model. This approach allows the company to reach its target prescribers and patients effectively, particularly for a prescription-only product like VASCEPA. By strengthening relationships with these key distribution partners, Amarin can optimize its supply chain, improve product availability, and potentially negotiate more favorable terms. Enhancing the efficiency and reach of these specialized channels can support broader market access and ensure consistent product delivery, which is crucial for maintaining and expanding market share in competitive pharmaceutical landscapes.

What Are AMRN's Competitive Advantages?

• Proprietary formulation and regulatory approval of VASCEPA as a prescription-only omega-3 fatty acid.
• Established commercial infrastructure and market presence for VASCEPA in key international markets.
• Clinical evidence supporting VASCEPA's efficacy in reducing triglyceride levels in severe hypertriglyceridemia.
• Strategic collaboration with Mochida Pharmaceutical Co., Ltd. for further development of its active pharmaceutical ingredient.

What Does AMRN Do?

Amarin Corporation plc, initially incorporated in 1989 as Ethical Holdings plc and subsequently rebranded in 1999, stands as a pharmaceutical company primarily dedicated to the development and commercialization of therapeutics for cardiovascular diseases. Headquartered in Dublin, Ireland, the company's operational focus is anchored by its flagship product, VASCEPA. This prescription-only omega-3 fatty acid product is specifically indicated as an adjunct to diet for reducing triglyceride levels in adult patients diagnosed with severe hypertriglyceridemia. This targeted therapeutic approach places Amarin within a critical segment of the global healthcare sector, addressing a significant and prevalent risk factor for major cardiovascular events. Amarin's commercial footprint spans across several key international markets, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's distribution strategy primarily involves selling its products to wholesalers and specialty pharmacy providers. This model facilitates efficient market penetration and ensures that VASCEPA is accessible through established pharmaceutical supply chains to healthcare professionals and, ultimately, to patients in need. The strategic selection of these diverse geographies highlights Amarin's ambition to capitalize on varying market dynamics and healthcare needs globally. In addition to its direct commercialization activities, Amarin actively pursues strategic partnerships to bolster its product pipeline and expand its therapeutic reach. A significant collaboration exists with Mochida Pharmaceutical Co., Ltd., focusing on the development and commercialization of novel drug products and indications. These initiatives are specifically based on the active pharmaceutical ingredient found in Vascepa, which is the omega-3 acid, eicosapentaenoic acid. This partnership not only demonstrates Amarin's commitment to leveraging the full therapeutic potential of its core compound but also signifies its proactive approach to innovation and market expansion within the competitive cardiovascular disease treatment landscape. With a workforce of 275 employees, Amarin continues to navigate the complexities of the biotechnology industry, aiming to fulfill unmet medical needs in lipid management and cardiovascular health.

What Products and Services Does AMRN Offer?

• Develops and commercializes therapeutics specifically for the treatment of cardiovascular diseases.
• Its flagship product is VASCEPA, a prescription-only omega-3 fatty acid medication.
• VASCEPA is used as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia.
• Sells its pharmaceutical products primarily to wholesalers and specialty pharmacy providers.
• Operates and commercializes products in the United States, Germany, Canada, Lebanon, and the United Arab Emirates.
• Engages in a collaboration with Mochida Pharmaceutical Co., Ltd. for drug development based on eicosapentaenoic acid.

How Does AMRN Make Money?

• Generates revenue through the sale of its prescription-only pharmaceutical product, VASCEPA.
• Distributes products through established channels, primarily targeting wholesalers and specialty pharmacy providers.
• Leverages strategic partnerships, such as with Mochida Pharmaceutical, for product development and commercialization of new indications.
• Focuses on market penetration and expansion of its lead product in key international geographies.

What Industry Does AMRN Operate In?

Amarin Corporation plc operates within the dynamic Biotechnology industry, specifically targeting the Healthcare sector's cardiovascular therapeutics segment. The company's primary focus on severe hypertriglyceridemia positions it within a market driven by the increasing global prevalence of cardiovascular diseases and associated risk factors. This landscape is characterized by ongoing research and development into lipid-lowering therapies and a demand for effective prescription treatments. Amarin's lead product, VASCEPA, competes with various pharmaceutical interventions and dietary supplements aimed at managing lipid profiles. The competitive environment includes both established pharmaceutical giants with broad cardiovascular portfolios and other specialized biotech firms. Amarin differentiates itself through the specific regulatory approval and prescription status of VASCEPA, emphasizing its role as a medically prescribed adjunct to diet. The industry is constantly evolving with new scientific discoveries, regulatory challenges, and shifts in treatment paradigms, requiring companies like Amarin to continuously adapt their commercial and development strategies.

Who Are AMRN's Key Customers?

• Wholesalers who distribute pharmaceutical products to pharmacies and hospitals.
• Specialty pharmacy providers that dispense specialized medications, often for chronic conditions.
• Healthcare professionals, including cardiologists and endocrinologists, who prescribe VASCEPA.
• Ultimately, adult patients diagnosed with severe hypertriglyceridemia who require triglyceride reduction.

Company Profile

Amarin Corporation plc operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO Aaron D. Berg. AMRN has traded publicly since 1993.

Return on equity for Amarin Corporation plc stands at -7.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 8.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.2%, the inverse of the P/E and a quick read on earnings relative to price.

AMRN Valuation & Market Position

With a $290M market cap, Amarin Corporation plc sits in the micro-cap segment of the market. Relative to its peer group, AMRN's quantitative score of 19/100 is below the peer average of 78/100.

Quarterly Financial Performance: Amarin Corporation plc

Revenue for Amarin Corporation plc came in at $42.2M during Q2 FY2026, a 6.5% contraction versus the preceding quarter. The company recorded a net loss of $7.7M, with diluted EPS of $-0.37. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, AMRN averaged $-0.33 in diluted EPS.

Amarin Corporation plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.88 places it in the distress zone, a signal of elevated financial risk.

Amarin Corporation plc has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 200.2% below estimates on average.

Over the past six months, Amarin Corporation plc insiders filed 42 SEC Form 4 transactions — 14 sales and 28 purchases. On net that is roughly 40K shares acquired (about $198K) — insiders putting money in tends to read as conviction.

AMRN Financials

AMRN Latest News

AMRN Analyst Consensus

AMRN MoonshotScore

AMRN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources